Global Open Angle Glaucoma Market, By Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma, Others), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Open Angle Glaucoma Market Analysis and Size
As per the International Agency for the Prevention of Blindness: 2017, glaucoma is second top cause of blindness and main cause of irreversible blindness globally. The increasing elderly population is one of the main factors for increasing incidence of glaucoma, which is anticipated to drive growth of the glaucoma therapeutics market in the near future. The increasing growth of open angle glaucoma market boosted by the rising cases of glaucoma and increase in R&D activities conducted by many pharmaceuticals’ companies
Data Bridge Market Research analyses a growth rate in the open angle glaucoma market in the forecast period 2023-2030. The expected CAGR of open angle glaucoma market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 5.2 million in 2022, and it would grow upto USD 7.12 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Open Angle Glaucoma Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma, Others), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Aerie Pharmaceuticals, Inc. (U.S.), Abbvie, Inc (U.S.), Bausch Health Companies Inc (Canada), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Fera Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), EyePoint Pharmaceuticals,Inc (U.S.) Amorphex Therapeutics Holdings, Inc (U.S.), Kubota Vision Inc (U.S.), Alcon (Switzerland), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Novartis AG (U.S.), Carl Zeiss Meditec AG (Germany), Nidek Co Ltd (India), Accutome, Inc (U.S.), AqueSys (U.S.), Iridex Corporation (U.S.) |
|
Market Opportunities |
|
Market Definition
The glaucoma is one of the top ocular disorders which results in the damage to the optic nerve. Glaucoma can cause vision loss and blindness. There are several drugs which are utilized for the diagnosis of this diseased condition. Some of them are alpha-adrenergic agonists, hyperosmotics, beta blockers, and carbonic anhydrase inhibitors. The most common types of glaucoma are primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG).
Open Angle Glaucoma Market Dynamics
Drivers
- Increase in Elderly Population
The elderly population is anticipated to increase the demand of the disease globally during the forecast period. As per the records of the WHO, the elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. Thus, this increasing population will suffer from more ocular disorders especially glaucoma. This boost the market growth.
- Growing Demand for Oral Drugs
Oral drugs is anticipated to boost the market growth. The segment is projected to increase the global market as most of the products are available in capsule form and tablet form and it is a very feasible route of administration especially for the elderly population.
Opportunities
- Increasing Occurrence of Blindness Cases
As per the records of the International Agency for the Prevention of Blindness, it is projected that about 80 million people will suffer from glaucoma in 2020, a huge increase from 20 million witnessed in 2010. In addition to this, more than 8 million people were bilaterally blind because of glaucoma, which is anticipated to increase to over 14 million by 2022.
- Growing Demand for Retail Pharmacies
The increase in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with suitable treatments could impede the growth of the global open angle glaucoma market during the forecast period.
- High Cost of Treatment
The increased expenditure related with the treatment of open angle glaucoma medications hamper the market growth. Beta blockers, antagonists, prostaglandins, alpha adrenergic agonists, and carbonic anhydrase inhibitors will hamper the market growth by increasing costs.
This open angle glaucoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the open angle glaucoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2020, the two glaucoma treatments launched by Micro Labs USA were dorzolamide 2% and dorzolamide-timolol. Micro Labs USA plans to issue new ophthalmic products in stages of FDA evaluation and development to meet the increasing demand.
- In 2019, Allergan Plc stated that the New Drug Application (NDA) for Bimatoprost Sustained-Release had been approved by the U.S. FDA. Bimatoprost SR would be the first-ever prolonged, reversible implant for the treatment of individuals with primary open-angle glaucoma or ophthalmic hypertension.
Global Open Angle Glaucoma Market Scope
The open angle glaucoma market is segmented on the basis of type, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Closed Angle Glaucoma (CAG)
- Open Angle Glaucoma (OAG)
- Secondary Glaucoma
- Congenital Glaucoma
- Others
Drug Class
- Beta Blockers
- Prostaglandins
- Alpha Adrenergic Agonist
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Open Angle Glaucoma Market Regional Analysis/Insights
The open angle glaucoma market is analyzed and market size insights and trends are provided by type, drug class, distribution channel and end-user as referenced above.
The major countries covered in the open angle glaucoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a huge growth for open angle glaucoma market throughout the forecasted period because of the strong repayment rules and high incidence of patient’s pool.
North America dominates the market because of the high incidences of glaucoma, and the economic stability which outcomes to increased healthcare spending. Additionally, huge population suffering from diabetes and other eye diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Open Angle Glaucoma Market Share Analysis
The open angle glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to open angle glaucoma market
Key players operating in the open angle glaucoma market include:
- Aerie Pharmaceuticals, Inc. (U.S.)
- Abbvie, Inc (U.S.)
- Bausch Health Companies Inc (Canada)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Fera Pharmaceuticals (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- EyePoint Pharmaceuticals,Inc (U.S.)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Kubota Vision Inc (U.S.)
- Alcon (Switzerland)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Novartis AG (U.S.)
- Carl Zeiss Meditec AG (Germany)
- Nidek Co Ltd (India)
- Accutome,Inc (U.S.)
- AqueSys (U.S.)
- Iridex Corporation (U.S.)
SKU-
